Reported about 10 hours ago
Neurocrine Biosciences, Inc. (NBIX) is highlighted as a notable investment choice by billionaire investor Cliff Asness, boasting a potential upside of 45.64%. The biopharmaceutical company focuses on treating neurological and psychiatric disorders, with flagship products like INGREZZA. Despite a recent adjustment in stock price targets by Canaccord Genuity, the firm projects robust sales growth through 2025. Asness, known for his successful investment strategies, continues to outperform the market, especially amid current economic volatility.
Source: YAHOO